Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. The company's lead compound is AKR-001, a novel long-acting FGF21 analogue. Akero plans to begin Phase 2 clinical studies of AKR-001 for the treatment of NASH.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/25/18 | $65,000,000 | Series A |
Apple Tree Partners Atlas Venture VenBio Versant Ventures | undisclosed |
| 12/12/18 | $70,000,000 | Series B |
Apple Tree Partners BVF Partners Cormorant Asset Management Janus Henderson Investors LifeSci Venture Partners Redmile Group Rock Springs Capital Tavistock Group VenBio Versant Ventures | undisclosed |
